DURGA-1

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)

Near Add Your Location

Sorting 33 by

Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Accepting patients
  • Show Principal Investigator
Sarah Cannon Research Institute
TriStar Centennial Medical Center
Nashville, TN
  • Accepting patients
  • Accepting patients
  • Accepting patients
University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
  • Accepting patients
  • Accepting patients
  • Accepting patients
  • Accepting patients
Swedish Cancer Institute
Swedish Edmonds Campus
Edmonds, WA
  • Not yet accepting

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.